Multiplex mutation screening by mass spectrometry: Evaluation of 820 cases from a personalized cancer medicine registry (The Journal of Molecular Diagnostics (2011) 13, (504-513)

摘要

In the article entitled, "Multiplex Mutation Screening by Mass Spectrometry: Evaluation of 820 Cases from a Personalized Cancer Medicine Registry" (Volume 13, pages 504-513 of the September 2011 issue of The Journal of Molecular Diagnostics), the corresponding author's disclosures were inadvertently omitted. The disclosures should have read as follows:CME Disclosure: CLC receives research support from Novartis, serves as a consultant/advisory board member for Novartis and Sequenom, and is a member of the speakers' bureau for Novartis. None of the other authors disclosed any relevant financial relationships.Dr. Corless asserts, "These fees were no way related to the work that we published, and my relationship with Novartis had no impact on the care of patients who consented to our Personalized Cancer Medicine Registry, as it was only a registry and not a clinical trial."